L4 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:30773 CAPLUS
DN 120:30773
TI **Oxadiazole** derivatives having acetylcholinesterase-inhibitory and muscarinic receptor agonist activity
IN Takasugi, Hisashi; Kuno, Atsushi; Ohkubo, Mitsuru
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9313083	A1	19930708	WO 1992-JP1658	19921218
	W: AU, CA, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1991-27533	19911231
				GB 1992-20904	19921005
	AU 9331714	A1	19930728	AU 1993-31714	19921218
				GB 1991-27533	19911231
				GB 1992-20904	19921005
				WO 1992-JP1658	19921218
	EP 619814	A1	19941019	EP 1993-900416	19921218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				GB 1991-27533	19911231
				GB 1992-20904	19921005
				WO 1992-JP1658	19921218
	JP 07502529	T2	19950316	JP 1992-511547	19921218
				GB 1991-27533	19911231
				GB 1992-20904	19921005
				WO 1992-JP1658	19921218
	US 5622976	A	19970422	US 1994-244904	19940624
				GB 1991-27533	19911231
				GB 1992-20904	19921005
				WO 1992-JP1658	19921218

Patel <10/13/2003>

OS MARPAT 120:30773
IT **151097-86-8P 151097-87-9P 151307-60-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acetylcholineesterase inhibitory and muscarinic receptor agonist activity of)
RN 151097-86-8 CAPLUS
CN 1,2,4-Oxadiazole-3-carboxamide, 5-(1-azabicyclo[2.2.2]oct-3-yl)-N-[1-(phenylmethyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 151097-87-9 CAPLUS
CN' 1,2,4-Oxadiazole-3-carboxamide, 5-(1-azabicyclo[2.2.2]oct-3-yl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 151307-60-7 CAPLUS
CN 1,2,4-Oxadiazole-3-carboxamide, 5-(4-nitrophenyl)-N-[1-(phenylmethyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151307-59-4
CMF C21 H21 N5 O4



CM 2

10069215.2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



AB The title compds. R1QZXAM [A = direct bond, lower alkylene, lower alkynylene; M = (un)substituted heterocyclic group contg. .gtoreq.1 N atom(s); Q = oxadiazolediyl; R1 = lower alkyl, (un)substituted heterocyclic group, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted aralkenyl; X = direct bond, CONR4, R8CN; R4 = H, alkyl; R8 = HO, protected HO group, CO, NHCO; Z = direct bond, vinyl (sic)], useful for the treatment of central nervous system disorders (e.g., amnesia, Alzheimer's disease, vascular dementia, etc.) mode data, are prepd. Thus, 3-ethoxycarbonyl-5-(quinucilidin-3-yl)-1,2,4-**oxadiazole** and 1-benzyl-4-(2-aminoethyl)piperidine were heated together in soln. at 100.degree. for 2 h and treated with an ethanolic soln. of HCl, producing 5-(quinuclidin-3-yl)-3-[[2-(1-benzylpiperidin-4-yl)ethyl]carbamoyl]-1,2,4-**oxadiazole** dihydrochloride, m.p. 210.degree. (decompn.).